Matrixyl 3000 vs Palmitoyl Hexapeptide-12
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7
Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Also: Biopeptide EL, Pal-VGVAPG
Palmitoyl hexapeptide-12 is the six-amino-acid sequence VGVAPG, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. It is sold under the trade name Biopeptide EL and pitched for firmness and elasticity, the bounce-back that fades with age. It is a cosmetic ingredient, not an FDA-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Matrixyl 3000 | Palmitoyl Hexapeptide-12 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Both peptides are matrikines, short collagen-derived signals the skin treats as repair instructions. Palmitoyl tripeptide-1 nudges fibroblasts to produce more collagen, elastin and fibronectin, the scaffolding that keeps skin firm. Palmitoyl tetrapeptide-7 works on the other side of the equation by tamping down release of interleukin-6, an inflammatory messenger that climbs with age and quietly accelerates matrix breakdown, which in turn is thought to limit collagen glycation damage. As with the original Matrixyl, the palmitoyl tails are there to ferry these water-loving peptides through the skin barrier. The combined claim is build more, lose less. | VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built. |
| Common Dosing | Limited community data available See research protocols | About 4% of the ingredient solution in a finished product Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, creams) |
| Typical Duration | Ongoing use for maintained effects | Manufacturer study ran one month; ongoing use for any maintained effect |
| Best Time to Take | Morning or as directed | Morning and/or evening skincare routine |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Matrixyl 3000 has a coherent, biologically reasonable mechanism, and in vitro studies do show its components stimulating fibroblast proliferation and synthesis of collagen types I, III, IV and VII, with the tetrapeptide reducing IL-6. The catch for a careful reader is that most of the supporting clinical work, including the commonly cited 12-week trials reporting reductions in wrinkles and skin laxity, originates from or was sponsored by the manufacturer rather than independent labs, and large published placebo-controlled trials specific to this exact complex are sparse. The strongest truly independent peptide evidence in this family is still the original Pal-KTTKS Matrixyl data. So Matrixyl 3000 is best described as a sensible, well-tolerated upgrade on paper with solid mechanistic and in vitro backing, but with human efficacy that rests heavily on industry sources rather than rigorous third-party trials. It targets collagen and inflammation, not muscle, so expectations should be texture and firmness, not Botox-like smoothing. | The best peer-reviewed work is a 2025 paper in ACS Applied Bio Materials (Ligorio and colleagues, with co-authors from Estee Lauder) that tracked the peptide in full-thickness human skin from a single donor. It showed penetration into the stratum corneum and epidermis, gel formation driven by calcium, reduced water loss and drying stress in delipidated skin (roughly comparable to 5 percent glycerol for drying stress), and stronger gels when mixed with collagen. Useful mechanistic data, but small samples and no living people. The appearance claims come from the manufacturer: a one-month, double-blind study in 10 women using 4 percent Biopeptide EL twice daily reported 33 percent better firmness and 20 percent better tone. That study is not in PubMed and is far too small to lean on. A separate 2023 trial of an elastin-like recombinant polypeptide built on the same VGVAPG repeat found improved elasticity after 28 days in 30 women, but that was a different molecule. Honest read: plausible biology, real skin penetration, no independent proof of visible results. |
Frequently Asked Questions: Matrixyl 3000 vs Palmitoyl Hexapeptide-12
What is the difference between Matrixyl 3000 and Palmitoyl Hexapeptide-12?
Matrixyl 3000 is a skin & hair peptide that matrixyl 3000 is sederma's follow-up to the original matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (pal-ghk) and palmitoyl tetrapeptide-7 (pal-gqpr). the idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. it is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence. Palmitoyl Hexapeptide-12 is a skin & hair peptide that palmitoyl hexapeptide-12 is the six-amino-acid sequence vgvapg, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. it is sold under the trade name biopeptide el and pitched for firmness and elasticity, the bounce-back that fades with age. it is a cosmetic ingredient, not an fda-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Matrixyl 3000 or Palmitoyl Hexapeptide-12?
Neither is universally "better" - the choice depends on your specific goals. Matrixyl 3000 is typically used for skin & hair purposes, while Palmitoyl Hexapeptide-12 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Matrixyl 3000 and Palmitoyl Hexapeptide-12 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Matrixyl 3000 and Palmitoyl Hexapeptide-12 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.